Individualized treatment improves symptoms and quality of life for women with PCOS.
3 citations
,
October 2015 in “EFSA supporting publications” Isoflavones may help with menopause symptoms but could be risky for women with hormone-sensitive cancers.
89 citations
,
November 2014 in “International Journal of Nanomedicine” Using nanostructured lipid carriers to deliver spironolactone could improve treatment for hair loss.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
14 citations
,
August 1943 in “Archives of Dermatology” Applying estradiol to skin causes local changes but not cancer.
4 citations
,
January 2011 Phenylpropanoid sucrose esters show potential as anticancer agents.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
1 citations
,
December 2015 in “Endocrinology” Decanoic acid may help treat PCOS by reducing androgen levels and improving glucose sensitivity.
July 2024 in “International Journal of Chemical and Biological Sciences” Glypican-4 may help indicate insulin sensitivity and lipid issues in women with PCOS.
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
November 2025 in “Frontiers in Endocrinology” Apigenin and ellagic acid may help manage PCOS symptoms.
3 citations
,
July 2018 in “JAAPA” Some birth control pills can cause hair loss, and switching to ones with less androgen should help.
Chemotherapy for breast cancer often causes significant and lasting hair loss.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
October 2018 in “International journal of clinical & experimental dermatology” Baicapil was effective in reducing hair loss and increasing hair growth in women with telogen effluvium.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
4 citations
,
May 2019 in “Journal of Clinical Oncology” Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
Baricitinib works better than methotrexate for severe alopecia areata.
4 citations
,
August 2024 in “PLoS ONE” Both injectable contraceptives lower testosterone and SHBG levels, with NET-EN having a greater effect than DMPA-IM.
44 citations
,
May 2022 in “Journal of Assisted Reproduction and Genetics”
Spironolactone may be a better acne treatment for adult women than antibiotics.
13 citations
,
January 2020 in “Nanoscale” Finasteride and baicalin in phospholipid vesicles effectively promote hair growth and increase follicle count.
January 2009 in “Journal of Pakistan Association of Dermatology” Systemic cyproterone acetate and 5% topical minoxidil are effective and safe for treating female pattern hair loss.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
35 citations
,
October 2005 in “European journal of pharmaceutics and biopharmaceutics” Polymers increased skin permeation and stability of steroid hormones in liposomal formulations.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.